Wakefield Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
PF
Wakefield Asset Management's XBI Position: Q1 2023 in Review
Wakefield Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 21,567 shares — an estimated $1.79M sold.
Wakefield Asset Management first reported a position in XBI in Q1 2022 and held it in 3 quarters. The position peaked at $1.79M in Q4 2022. 712 funds tracked by Wall St. Rank hold XBI as of Q1 2023.
- Wakefield Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
- Wakefield Asset Management sold 21,567 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $1.79M.
- Wakefield Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 3 quarters.
- Wakefield Asset Management's State Street SPDR S&P Biotech ETF position peaked at $1.79M in Q4 2022.
- 712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.
Based on Wakefield Asset Management's 13F filing for Q1 2023, filed 2 May 2023.